Journal
THROMBOSIS RESEARCH
Volume 110, Issue 5-6, Pages 311-315Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0049-3848(03)00418-3
Keywords
prostaglandins; nuclear receptors; activation
Categories
Funding
- NHLBI NIH HHS [HL 70128, HL 61364] Funding Source: Medline
- NIDDK NIH HHS [DK-09942] Funding Source: Medline
Ask authors/readers for more resources
Deletion of membrane receptors for prostaglandins has revealed their importance in diverse biological systems. Some evidence has accrued to support the contention that they may also ligate nuclear receptors, particularly peroxisomal proliferator activator receptors (PPARs). This is most pronounced in the case of 15-deoxy PGJ(2), a cyclopentanone derivative of PGJ(2) as a ligand for PPARgamma. However, while this compound can ligate the PPAR, the quantities formed in vivo suggest that this is an unlikely endogenous ligand. Furthermore, biosynthesis is unaltered in murine atherosclerosis and other inflammatory and metabolic disorders where activation of this PPAR has been implicated. The suggestion that prostaglandins serve as endogenous ligands for nuclear receptors is presently configured on the use of synthetic compounds and immunoreactive quantitation of dubious validity. The application of quantitatively precise and sensitive physicochemical methodology will enhance experiments designed to address this hypothesis. (C) 2003 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available